Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Gynecol Oncol
; 182: 124-131, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262235
3.
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Gynecol Oncol
; 177: 173-179, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716223
4.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol
; 166(2): 219-229, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690498
5.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075393
6.
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Gynecol Oncol
; 160(2): 539-546, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229045
7.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
8.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(2): 191-226, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545690
9.
Image-Guided Percutaneous Thermal Ablation of Oligometastatic Ovarian and Non-Ovarian Gynecologic Tumors.
J Vasc Interv Radiol
; 32(5): 729-738, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33608192
10.
Mechanisms of PARP inhibitor resistance in ovarian cancer.
Curr Opin Obstet Gynecol
; 32(1): 36-41, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31815769
11.
Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Curr Opin Obstet Gynecol
; 32(1): 84-90, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804230
12.
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
Gynecol Oncol
; 154(3): 461-466, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257009
13.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
14.
Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Gynecol Oncol
; 150(2): 227-232, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925470
15.
The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Curr Opin Obstet Gynecol
; 30(1): 44-50, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29227302
16.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
17.
Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
Gynecol Oncol
; 147(3): 503-508, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28964622
18.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
19.
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
Br J Cancer
; 114(12): 1412-20, 2016 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27253175
20.
Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.
Gynecol Oncol
; 141(2): 379-385, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827964